The use of belimumab on patients with both systemic lupus erythematosus and immune thrombocytopenia: A retrospective cohort study
Lupus · 2024
DOI: 10.1177/09612033241241576 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Lupus, 2024. Verfasst von Qi Wu und 4 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Traditional Chinese Medicine Syndrome, Department of Rheumatology, The First Affiliated Hospital of Guangzhou University of C…. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Purpura, Thrombocytopenic, Idiopathic, Thrombocytopenia, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
Objective
The objective of this study is to provide a description of a group of retrospective cohort outcomes in patients with systemic lupus erythematosus (SLE) complicated with immune thrombocytopenia (ITP) receiving belimumab.
Methods
This study reports on the treatment of 10 female patients (mean age 34.3 ± 14.0 years, mean weight 58.7 ± 18.2 kg) with both SLE and ITP who received belimumab in addition to basic drug therapy. The belimumab treatment regimen consisted of a dosage of 10 mg/kg, with an initial infusion every 2 weeks for the first 3 doses, followed by an infusion every 4 weeks.
Results
Ten patients were included in the study. The overall response rate of thrombocytopenia was 90% after treatment. The parameters such as platelet count, lymphocyte count, erythrocyte count, hemoglobin, dsDNA, C3, and C4 were significantly improved ( p < .05). The SLE Disease Activity Index (SLEDAI), British Islet lupus Assessment Group 2004 (BILAG-2004), and Physician Global assessment (PGA) scores were significantly decreased ( p < .05). There were no significant differences in glutamic pyruvic transaminase (ALT), glutamic oxaloacetic transaminase (AST), and serum creatinine (Scr) before and after treatment ( p > .05).
Conclusion
Belimumab shows promising clinical outcomes in the treatment on patients with both SLE and ITP. Further studies are needed to validate these findings in larger patient populations and compare the efficacy of belimumab with other treatments for SLE complicated with ITP. Long-term response rates and adverse events associated with belimumab treatment also warrant further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Traditional Chinese Medicine Syndrome, Department of Rheumatology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
- The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, China.
- The Third Hospital of Mianyang (Sichuan Mental Health Center), Mianyang, China.
ORCID-Profile: Qiang Xu
Zitieren
APA
Wu, Q., Zhao, M. X., Huang, X. S., Lin, C. S., & Xu, Q. (2024). The use of belimumab on patients with both systemic lupus erythematosus and immune thrombocytopenia: A retrospective cohort study. Lupus. https://doi.org/10.1177/09612033241241576
Vancouver
Wu Q, Zhao MX, Huang XS, Lin CS, Xu Q. The use of belimumab on patients with both systemic lupus erythematosus and immune thrombocytopenia: A retrospective cohort study. Lupus. 2024. doi:10.1177/09612033241241576
BibTeX
@article{Wu2024,
author = {Wu, Qi and Zhao, Ming-Xue and Huang, Xiao-Shan and Lin, Chang-Song and Xu, Qiang},
title = {The use of belimumab on patients with both systemic lupus erythematosus and immune thrombocytopenia: A retrospective cohort study},
journal = {Lupus},
year = {2024},
doi = {10.1177/09612033241241576}
}
EUVIMED